Abstract：
BACKGROUND: Cachexia is associated with poor survival rates. In the clinical setting, the diagnosis of cancer cachexia is challenging. The cachexia index (CXI), a new index for predicting survival time, is a promising tool for diagnosing cancer cachexia; however, its efficacy in predicting patient survival has not been validated.
OBJECTIVE: This meta-analysis and systematic review aimed to explore the CXI\'s prognostic value in patients with cancer.
METHODS: The PubMed, Embase, MEDLINE, and Cochrane Library databases were searched for relevant studies to determine the association between CXI findings and prognosis.
METHODS: The outcomes were overall survival (OS), progression-, disease-, and recurrence-free survival (PFS/DFS/RFS) rates, and the rate of complete response.
METHODS: The QUality In Prognostic Studies (QUIPS) tool was used to evaluate the quality of the included trials. This meta-analysis comprised 14 studies involving 2777 patients. A low CXI was associated with decreased OS (hazard ratio [HR] 2.34, 95% confidence interval [CI] 2.01-2.72; P < .001), PFS/DFS/RFS (HR 1.93, 95% CI 1.68-2.22; P < .001), and complete response (odds ratio [OR] 0.49, 95% CI 0.36-0.66; P < .001). Patients with a low CXI had a lower body mass index (mean difference [MD] -0.75, 95% CI -1.00 to 0.50; P < .001), skeletal muscle index (standardized MD -0.80, 95% CI -0.98 to -0.61; P < .001), and serum albumin level (MD -0.23, 95% CI -0.26 to -0.20; P < .001); and a higher neutrophil-lymphocyte ratio (MD 1.88, 95% CI 1.29-2.47; P < .001) and more advanced disease stages (OR 0.80, 95% CI 0.71-0.91; P = .001).
CONCLUSIONS: A low CXI was found to be associated with poor survival in patients with cancer. While the CXI is a promising marker for predicting cancer cachexia, further studies are required to verify its usefulness.
OBJECTIVE: This meta-analysis and systematic review aimed to explore the CXI\'s prognostic value in patients with cancer.
METHODS: The PubMed, Embase, MEDLINE, and Cochrane Library databases were searched for relevant studies to determine the association between CXI findings and prognosis.
METHODS: The outcomes were overall survival (OS), progression-, disease-, and recurrence-free survival (PFS/DFS/RFS) rates, and the rate of complete response.
METHODS: The QUality In Prognostic Studies (QUIPS) tool was used to evaluate the quality of the included trials. This meta-analysis comprised 14 studies involving 2777 patients. A low CXI was associated with decreased OS (hazard ratio [HR] 2.34, 95% confidence interval [CI] 2.01-2.72; P < .001), PFS/DFS/RFS (HR 1.93, 95% CI 1.68-2.22; P < .001), and complete response (odds ratio [OR] 0.49, 95% CI 0.36-0.66; P < .001). Patients with a low CXI had a lower body mass index (mean difference [MD] -0.75, 95% CI -1.00 to 0.50; P < .001), skeletal muscle index (standardized MD -0.80, 95% CI -0.98 to -0.61; P < .001), and serum albumin level (MD -0.23, 95% CI -0.26 to -0.20; P < .001); and a higher neutrophil-lymphocyte ratio (MD 1.88, 95% CI 1.29-2.47; P < .001) and more advanced disease stages (OR 0.80, 95% CI 0.71-0.91; P = .001).
CONCLUSIONS: A low CXI was found to be associated with poor survival in patients with cancer. While the CXI is a promising marker for predicting cancer cachexia, further studies are required to verify its usefulness.
摘要：
背景：恶病质与低生存率相关。在临床上，癌症恶病质的诊断具有挑战性。恶病质指数（CXI），预测生存时间的新指标，是诊断癌症恶病质的有前途的工具；然而，其预测患者生存率的有效性尚未得到验证.
目的：本荟萃分析和系统评价旨在探讨CXI在癌症患者中的预后价值。
方法：PubMed，Embase,MEDLINE,我们在CochraneLibrary数据库中搜索相关研究,以确定CXI结果与预后之间的关联.
方法：结果是总生存期（OS），进度-,疾病-，和无复发生存率（PFS/DFS/RFS），以及完全反应率。
方法：使用预后研究质量（QUIPS）工具评估纳入试验的质量。这项荟萃分析包括14项研究，涉及2777名患者。低CXI与OS降低相关(风险比[HR]2.34,95%置信区间[CI]2.01-2.72;P<.001),PFS/DFS/RFS（HR1.93，95%CI1.68-2.22；P<.001），和完全缓解（比值比[OR]0.49，95%CI0.36-0.66；P<.001）。低CXI患者的体重指数较低（平均差异[MD]-0.75，95％CI-1.00至0.50；P<.001），骨骼肌指数（标准化MD-0.80，95%CI-0.98至-0.61；P<.001），和血清白蛋白水平（MD-0.23，95％CI-0.26至-0.20；P<.001）；中性粒细胞-淋巴细胞比率较高（MD1.88，95％CI1.29-2.47；P<.001）和更晚期的疾病阶段（OR0.80，95％CI0.71-0.91；P=.001）。
结论：发现低CXI与癌症患者的低生存率相关。虽然CXI是预测癌症恶病质的有希望的标志物，需要进一步的研究来验证其有效性。
目的：本荟萃分析和系统评价旨在探讨CXI在癌症患者中的预后价值。
方法：PubMed，Embase,MEDLINE,我们在CochraneLibrary数据库中搜索相关研究,以确定CXI结果与预后之间的关联.
方法：结果是总生存期（OS），进度-,疾病-，和无复发生存率（PFS/DFS/RFS），以及完全反应率。
方法：使用预后研究质量（QUIPS）工具评估纳入试验的质量。这项荟萃分析包括14项研究，涉及2777名患者。低CXI与OS降低相关(风险比[HR]2.34,95%置信区间[CI]2.01-2.72;P<.001),PFS/DFS/RFS（HR1.93，95%CI1.68-2.22；P<.001），和完全缓解（比值比[OR]0.49，95%CI0.36-0.66；P<.001）。低CXI患者的体重指数较低（平均差异[MD]-0.75，95％CI-1.00至0.50；P<.001），骨骼肌指数（标准化MD-0.80，95%CI-0.98至-0.61；P<.001），和血清白蛋白水平（MD-0.23，95％CI-0.26至-0.20；P<.001）；中性粒细胞-淋巴细胞比率较高（MD1.88，95％CI1.29-2.47；P<.001）和更晚期的疾病阶段（OR0.80，95％CI0.71-0.91；P=.001）。
结论：发现低CXI与癌症患者的低生存率相关。虽然CXI是预测癌症恶病质的有希望的标志物，需要进一步的研究来验证其有效性。
